Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialisation of transformative therapies for patients living with central nervous system disorders with high unmet medical needs, has named Diane Wilfong as its new director, it was reported yesterday.
Wilfong has more than 30 years of financial and operations experience in large, multinational companies, including most presently serving as senior vice president, controller and chief accounting officer of Gilead Sciences Inc. Prior to joining Gilead in 2016, she was vice president, controller and principal accounting officer at Computer Sciences Corporation. From 2009 to 2014, she led the accounting and tax functions at Caesars Entertainment and spearheaded a major financial transformation initiative along with key elements of a public offering, and was responsible for Sarbanes-Oxley compliance in her role. Prior, she spent 10 years at Eastman Kodak Company in a series of executive, operational and financial roles, including serving as general manager of the company's Graphics and Printing Systems group, and later as the corporate controller and chief accounting officer. Prior to Kodak, she held positions at Corning and at Price Waterhouse.
Jon Congleton, president and chief executive officer of Impel, said, 'Impel is rapidly advancing a late-stage pipeline of therapies for CNS disorders with high unmet medical needs, all of which are the result of over a decade of pioneering a unique approach to drug delivery. We are pleased to welcome Diane to Impel's board, and we look forward to leveraging her dynamic leadership experience and extensive background in finance as we continue to grow into a fully integrated R&D and commercial organisation.'
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference